Drug
Vanzacaftor clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vanzacaftor is read from its arms, and is right about nine times in ten.
Testing it · 3
- An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy ParticipantsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT05867147Written as Vanzacaftor
- A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic FibrosisCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT03912233Written as VX-121
- Study of VX-121 in Healthy Subjects and in Subjects With Cystic FibrosisCompletedPhase 1/2Vertex Pharmaceuticals IncorporatedNCT03768089Written as VX-121 (Suspension)
Codes
What other systems call vanzacaftor · ClinicalTrials.gg INT002186
- MeSH (NLM) C000731979vanzacaftorOne source NLM
- UNII (FDA) COM1POP492VANZACAFTORConfirmed FDA, NLM
- NCI Thesaurus C188560VanzacaftorOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731979 | vanzacaftor | One source NLM |
| UNII (FDA) | COM1POP492 | VANZACAFTOR | Confirmed FDA, NLM |
| NCI Thesaurus | C188560 | Vanzacaftor | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.